Podcast
Monty Pal
Value assessment frameworks in oncology: championing concordance through shared standards
Summary
The ASCO Value Framework Net Health Benefit Score (ASCO-NHB) and the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS), introduced in 2015, are essential tools for assessing the relative benefit of cancer therapies. Both ASCO and ESMO continually refine these frameworks and engage with stakeholders to better understand and communicate the value of new treatments. As the global burden of cancer grows, their collaborative efforts aim to foster a coherent approach to managing and reducing this impact.
As rapidly evolving tools under the constant rigorous review and development by both ASCO and ESMO’s expert task forces, the ASCO Value Framework Net Health Benefit Score (ASCO-NHB) and the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) were both launched in 2015 to assess the relative benefit of cancer therapies and were recently compared. Both societies are working to better understand and measure the value of new cancer therapies and are facilitating a broader discussion with stakeholders that, hopefully, will lead to a coherent approach to confronting the global burden of cancer. The time to do so is now.....
ASCO, ESMO, NHB, MCBS
Related Topics
You May Also Like
Monty Pal
Article
Di Maria Jiang, Kelvin K. W. Chan, Raymond W. Jang, Christopher Booth, Geoffrey Liu, Eitan Amir, Robert Mason, Louis Everest, Elena Elimova
Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations
Article
Shun-Long Ou, Jing Luo, Hua Wei, Xiao-Li, Qian Jiang
Value assessment of PD-1/PD-L1 inhibitors in the treatment of esophageal and gastrointestinal cancers
Article
Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
Article
Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
Article
Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS